Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)
![Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)](https://www.abcam.com/ps/products/218/ab218518/Images/ab218518-273941-anti-psgl-1-antibody-psgl1-1601-immunohistochemistry.jpg "Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)")
Key features and details
- Mouse monoclonal [PSGL1/1601] to PSGL-1
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-PSGL-1 antibody [PSGL1/1601]
See all PSGL-1 primary antibodies -
Description
Mouse monoclonal [PSGL1/1601] to PSGL-1 -
Host species
Mouse -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Human PSGL-1.
Database link: Q14242 -
Positive control
- IHC-P: Human spleen and tonsil tissues.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.05% Sodium azide
Constituents: 99% PBS, 0.05% BSA -
Concentration information loading... -
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
PSGL1/1601 -
Isotype
IgG1 -
Research areas
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)
Immunohistochemical analysis of formalin-fixed and paraffin-embedded human tonsil tissue labeling PSGL-1 with ab218518 at 2 μg/mL dilution, followed by conjugation to the secondary antibody.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)](https://www.abcam.com/ps/products/218/ab218518/Images/ab218518-273939-anti-psgl-1-antibody-psgl1-1601-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PSGL-1 antibody [PSGL1/1601] (ab218518)Immunohistochemical analysis of formalin-fixed and paraffin-embedded human spleen tissue labeling PSGL-1 with ab218518 at 2 μg/mL dilution, followed by conjugation to the secondary antibody.
